Dose Escalation Study for Primary Hepatocellular Carcinoma

Not Applicable

Completed

Conditions: Carcinoma, Hepatocellular

Interventions: Radiation: Stereotactic Body Radiation

Registration Number: NCT00243841

Lead Sponsor: Indiana University School of Medicine

Brief Summary: The purpose of this study is to determine the maximum tolerated dose of limited fractions of large dose radiation in an effort to achieve a biologically potent cancer therapy in selected patients with primary hepatocellular carcinoma.

Detailed Description: Despite recent advances in early detection and diagnosis, only 30-40% of patients with hepatocellular carcinoma may benefit from radical therapies. Liver transplantation offers the best chance for cure. Surgical resection has been the only other potentially curative option, but the majority of patients are not candidates for resection. This reflects the usual comorbidity of severe underlying liver disease that either precludes surgery or makes the surgical approach extremely dangerous.

Recruitment & Eligibility

Status: COMPLETED

Sex: All

Target Recruitment: 77

Inclusion Criteria

Evaluation by the Surgery and/or Liver Transplant Team has been performed and the patient is not considered a candidate for either "standard" therapy to target area (upper abdomen)

Adequate liver function defined as:
- total bilirubin < 3mg/dl, albumin > 2.5 g/dl
- normal PT/PTT unless on anticoagulants
- mild elevation of liver enzymes acceptable (must be less than three times upper limit of normal)
Adequate renal function (creatinine < 1.8 mg/dl or creatinine clearance ≥ 50 ml/min)
Adequate bone marrow reserve:
- ANC count ≥ 1500 mm3
- Platelets ≥ 50,000/mm3
- Hemoglobin > 9 g/dL

NOTE: Lab values must be obtained within 2 weeks prior to being registered for protocol therapy.

Exclusion Criteria

No history of systemic lupus erythematous, rheumatoid arthritis, systemic sclerosis or scleroderma
No chemotherapy within 14 days before radiotherapy (chemotherapy may cause transient hepatitis with hepatomegaly)
No subsequent chemotherapy planned within 2 weeks of radiotherapy
No active liver infection
No acute Hepatitis. Definition of active disease:
- Hepatitis A: Acute hepatitis determined by presence of Anti-HAV- IgM
- Hepatitis B:
  1. HBsAg (HB surface Antigen): present in patients with acute and chronic hepatitis
  2. HBV DNA present in patients with active viral replication in amounts greater than 100,000 copies
  3. HBeAg is present in wild type HBV infection and suggests active replication
  4. Anti-HBs: Antibody against HBsAg appears after HBV infections and confers immunity
  5. Anti-HBc-IgM: Antibody against HBcAg, fraction IgM, present in acute infection and often could be detected during periods of high viral replication in chronic disease
  6. Anti-HBc-IgG: is present in chronic disease

Study & Design

Study Type: INTERVENTIONAL

Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Radiation Treatment Arm :A	Stereotactic Body Radiation	Patients with a score of Childs A Will receive 3 fractions of radiation over 5-10 days
Radiation Treatment Arm: B	Stereotactic Body Radiation	Patients with a score of Childs B will receive 5 fractions of radiation over 2-6 weeks.

Primary Outcome Measures

Name	Time	Method
Number of Patients With DLTs	6 weeks	Number of patients experiencing a Dose Limiting Toxicity during the Phase I portion of the trial.
6 Month Local In-field Control	6 months	Percent of patients and the 95% Binomial Confidence interval who were free of in-field progression at 6 months following treatment for the patients in Phase II

Secondary Outcome Measures

Name	Time	Method
Overall Survival	Up to 8 years	Kaplan-Meier Analysis will be used to calculate the median and 95% CI for overall survival. This will be calculated from the time of treatment until death. If a patient did not die, the patient will be censored at their last known alive date.
Time to In-field Failure	up to 4 yrs	Kaplan-Meier Analyses will be used to calculate the median and 95% Confidence Interval for the time until in-field failure. This will be calculated from the time of treatment until the time of in-field failure. If a patient did not have in-field failure, the patient will be censored at their last evaluation date.
Phase II: Number of Patients With Treatment Related Grade 3 or 4 Adverse Events	up to 4 years	Number of unique patients who had grade 3 or 4 adverse events that were possibly, probably or definitely related to study treatment.